156 related articles for article (PubMed ID: 36833798)
21. Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States.
Golabi P; Paik J; Hwang JP; Wang S; Lee HM; Younossi ZM
Liver Int; 2019 Apr; 39(4):748-757. PubMed ID: 30597715
[TBL] [Abstract][Full Text] [Related]
22. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.
Shao C; Ye J; Li F; Feng S; Wang W; Zhong B
Dig Liver Dis; 2019 Oct; 51(10):1392-1399. PubMed ID: 30928418
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis.
Ajmera V; Wang N; Xu H; Liu CT; Long MT
Aliment Pharmacol Ther; 2023 May; 57(10):1143-1150. PubMed ID: 36924053
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic Fatty Liver Disease and Associated Risk Factors in a Community-Based Sample of Mexican-Origin Adults.
Garcia DO; Morrill KE; Lopez-Pentecost M; Villavicencio EA; Vogel RM; Bell ML; Klimentidis YC; Marrero DG; Thomson CA
Hepatol Commun; 2022 Jun; 6(6):1322-1335. PubMed ID: 35076162
[TBL] [Abstract][Full Text] [Related]
25. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
[TBL] [Abstract][Full Text] [Related]
26. Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018.
Wang T; Xi Y; Raji A; Crutchlow M; Fernandes G; Engel SS; Zhang X
Ann Hepatol; 2024; 29(1):101154. PubMed ID: 37742743
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
28. Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity.
Khamseh ME; Malek M; Abbasi R; Taheri H; Lahouti M; Alaei-Shahmiri F
Metab Syndr Relat Disord; 2021 Apr; 19(3):167-173. PubMed ID: 33259744
[No Abstract] [Full Text] [Related]
29. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
[TBL] [Abstract][Full Text] [Related]
30. Association between hypertension and the prevalence of liver steatosis and fibrosis.
Fu H; Yu H; Zhao Y; Chen J; Liu Z
BMC Endocr Disord; 2023 Apr; 23(1):85. PubMed ID: 37081417
[TBL] [Abstract][Full Text] [Related]
31. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
Lee YH; Kim KJ; Yoo ME; Kim G; Yoon HJ; Jo K; Youn JC; Yun M; Park JY; Shim CY; Lee BW; Kang SM; Ha JW; Cha BS; Kang ES
J Hepatol; 2018 Apr; 68(4):764-772. PubMed ID: 29175242
[TBL] [Abstract][Full Text] [Related]
32. Dietary inflammatory index in relation to the progression of hepatic steatosis and liver fibrosis: evaluation by elastography/Fibroscan.
Miryan M; Rashid SA; Navashenaq JG; Soleimani D; Nematy M; Moludi J
BMC Gastroenterol; 2024 Apr; 24(1):128. PubMed ID: 38589782
[TBL] [Abstract][Full Text] [Related]
33. NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis.
Fleischman MW; Budoff M; Zeb I; Li D; Foster T
World J Gastroenterol; 2014 May; 20(17):4987-93. PubMed ID: 24803810
[TBL] [Abstract][Full Text] [Related]
34. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
[TBL] [Abstract][Full Text] [Related]
35. Awareness, Knowledge, and Misperceptions Related to Nonalcoholic Fatty Liver Disease in a Community Sample of Mexican-Origin Women: A Mixed Methods Study.
Morrill KE; Crocker RM; Hingle MD; Thomson CA; Garcia DO
Front Public Health; 2021; 9():626428. PubMed ID: 34485209
[No Abstract] [Full Text] [Related]
36. Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease.
Papandreou D; Karabouta Z; Pantoleon A; Rousso I
Appetite; 2012 Dec; 59(3):939-44. PubMed ID: 23000278
[TBL] [Abstract][Full Text] [Related]
37. Triglyceride to high-density lipoprotein cholesterol ratio is an independent predictor of liver fibrosis among pediatrics non-alcoholic fatty liver disease.
Ting YW; Jalaludin MY; Zaini AA; Mohamed R
Front Endocrinol (Lausanne); 2022; 13():1071350. PubMed ID: 36589844
[TBL] [Abstract][Full Text] [Related]
38. Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017-2018.
Heredia NI; Zhang X; Balakrishnan M; Daniel CR; Hwang JP; McNeill LH; Thrift AP
Prev Med; 2022 Jan; 154():106903. PubMed ID: 34861339
[TBL] [Abstract][Full Text] [Related]
39. Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study.
Seeberg KA; Hofsø D; Borgeraas H; Grimnes JO; Fatima F; Seeberg LT; Kvan NP; Svanevik M; Hertel JK; Hjelmesæth J
BMC Gastroenterol; 2022 Nov; 22(1):448. PubMed ID: 36336684
[TBL] [Abstract][Full Text] [Related]
40. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
